Document is current
Any future updates will be listed below
-
Authors
Ipas, Hélène
Gouws, Ellen B
Abell, Nathan S https://orcid.org/0000-0003-1098-5395
Chiou, Po-Chin https://orcid.org/0009-0008-0780-1966
Devanathan, Sravan K
Hervé, Solène https://orcid.org/0000-0002-5015-8493
Lee, Sidae
Mercado, Marvin
Reinsborough, Calder
Halabelian, Levon
Arrowsmith, Cheryl H
Xhemalçe, Blerta https://orcid.org/0000-0002-0517-9607
-
Funding
Funding for this research was provided by:
Welch Foundation (F1859)
HHS | NIH | National Institute of General Medical Sciences (R01 GM127802)
DOD | USA | MEDCOM | Congressionally Directed Medical Research Programs (W81XWH-16-1-0352)
Storm Therapeutics
UT | UT | College of Natural Sciences, University of Texas at Austin
Structural Genomics Consortium (1097737)
AbbVie US | AbbVie Canada
Bayer AG | Bayer Canada
Boehringer Ingelheim
Canada Foundation for Innovation
Eshelman Institute for Innovation
Genome Canada (OGI-055)
Innovative Medicines Initiative (ULTRA-DD grant no. 115766)
Janssen
Merck KGaA
Darmstadt, Germany, MSD
Novartis AG | Novartis Pharma
MDECEC | Ontario Ministry of Research and Innovation
Innovation and Science
Pfizer
São Paulo Research Foundation-FAPESP
Takeda
Wellcome
- License Information
-
More Information
Article History
Received: 27 November 2023
Revised: 20 December 2023
Accepted: 3 January 2024
First Online: 23 January 2024
Disclosure and competing interests statement
: The authors declare no competing interests.
